Literature DB >> 31773674

MiR-146a alleviates inflammation of acute gouty arthritis rats through TLR4/MyD88 signal transduction pathway.

X Chen1, Q Gao, L Zhou, Y Wang, R-R Sun, Z-Y Zhang.   

Abstract

OBJECTIVE: The aim of this study was to explore the effect of micro-ribonucleic acid (miR)-146a on acute gouty arthritis rats through Toll-like receptor-4/myeloid differentiation factor 88 (TLR4/MyD88) signal transduction pathway.
MATERIALS AND METHODS: A total of 30 clean-grade Sprague-Dawley rats were divided into three groups, including agomiR-146a group (n=10), antagomiR-146a group (n=10) and negative control group (NC, n=10). The model was successfully established via a one-time injection of sodium urate into ankle joint cavity. Subsequently, agomiR-146a (10 μL), antagomiR-146a (10 μL) and normal saline (10 μL) were intrathecally injected into rats in the three groups at 1 h before injection and 12 h, 24 h, 48 h and 72 h after injection, respectively. The ankle joint swelling index, joint dysfunction index and joint inflammation index of rats in the three groups were closely monitored. After 72 h of observation, the rats were euthanized, and synovial tissues were collected from the knee joint. The expression and distribution of nuclear factor-κB (NF-κB) in synovial tissues were detected using the immunohistochemical method. Meanwhile, the expression levels of inflammatory factors, including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) were detected via enzyme-linked immunosorbent assay. Furthermore, the mRNA and protein expression levels of TLR4 and MyD88 were detected via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blotting, respectively.
RESULTS: No statistically significant differences in the joint swelling index, joint dysfunction index, joint inflammation index, TLR4 and MyD88 and related inflammatory factors were found between the NC group and antagomiR-146a group. Compared with the NC group, agomiR-146a group showed markedly reduced ankle joint swelling index (p<0.05). Meanwhile, joint landing behavior and inflammatory swelling were significantly relieved in the agomiR-146a group (p<0.05). The mRNA and protein expression levels of TLR4 and MyD88 were remarkably decreased as well (p<0.05). Furthermore, the expression and distribution of NF-κB in synovial tissues of agomiR-146a group was markedly reduced when compared with the NC group (p<0.05). In addition, agomiR-146a group exhibited significantly lower expression levels of inflammatory factors (TNF-α, IL-1 and IL-6) in synovial tissues (p<0.05).
CONCLUSIONS: MiR-146a alleviates joint inflammation of acute arthritis in rats through the TLR4/MyD88/NF-κB signaling pathway, which may become a new therapeutic target.

Entities:  

Year:  2019        PMID: 31773674     DOI: 10.26355/eurrev_201911_19415

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  MicroRNA-142-3p facilitates inflammatory response by targeting ZEB2 and activating NF-κB signaling in gouty arthritis.

Authors:  Yao Lu; Li Fang; Xiangfeng Xu; Yanying Wu; Jiajia Li
Journal:  Cell Cycle       Date:  2022-03-03       Impact factor: 5.173

2.  Investigation of the Effects and Mechanisms of Dendrobium loddigesii Rolfe Extract on the Treatment of Gout.

Authors:  Kai-Hui Zhang; Mei-Qi Wang; Lu-Ling Wei; Cheng-Jing Feng; Yu-Si Zhang; Jian-Bei Teng
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-30       Impact factor: 2.629

Review 3.  Role of microRNA alternation in the pathogenesis of gouty arthritis.

Authors:  Zhipan Luo; Fan Yang; Shaocheng Hong; Jianpeng Wang; Bangjie Chen; Liangyun Li; Junfa Yang; Yan Yao; Chenchen Yang; Ying Hu; Shuxian Wang; Tao Xu; Jun Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

4.  Identification of Interleukin-1-Beta Inhibitors in Gouty Arthritis Using an Integrated Approach Based on Network Pharmacology, Molecular Docking, and Cell Experiments.

Authors:  Liying Zeng; Zekun Lin; Pan Kang; Meng Zhang; Hongyu Tang; Miao Li; Kun Xu; Yamei Liu; Ziyun Jiang; Shaochuan Huo
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-19       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.